Julia Shor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Julia Shor has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Christopher Marshall
Department of Gastroenterology, University of Massachusetts Medical School, Worcester, MA, USA,
1 shared publication Gustavo Churrango
Department of Gastroenterology, University of Massachusetts Medical School, Worcester, MA, USA,
1 shared publicationNooshin Hosseini
Department of Gastroenterology, Mount Sinai Hospital, New York, NY, USA
1 shared publication
Latest Publications
- Open Access
- 1 February 2019
- Published by Taylor & Francis in Clinical and Experimental Gastroenterology
- Vol. ume 12, 111-120
Management of microscopic colitis: challenges and solutions
Microscopic colitis (MC) is a chronic inflammatory bowel disease characterized by nonbloody diarrhea in the setting of normal appearing colonic mucosa. MC has two main subtypes based on histopathologic features, collagenous colitis and lymphocytic colitis. Management of both subtypes is the same, with treatment goal of reducing the number of bowel movements and improving consistency. First-line treatment involves counseling the patient about decreasing their risk factors, like discontinuing smoking and avoiding medications with suspected association such as NSAIDs, proton pump inhibitor, ranitidine, and sertraline. Starting loperamide for immediate symptomatic relief is used as an adjunct to therapy with glucocorticoids. Budesonide is considered first-line treatment for MC given its favorable side effect profile and good efficacy, though relapse rates are high. Systemic glucocorticoids should be reserved to patients unable to take budesonide. In glucocorticoid refractory disease, medications that have been tried include cholestyramine, bismuth salicylate, antibiotics, probiotics, aminosalicylates, immunomodulators, and anti-tumor necrosis factor-alpha inhibitors. More research is needed for the creation of a systematic stepwise approach for relapsing and refractory disease.
- 1 February 2019
- Published by Taylor & Francis in Clinical and Experimental Gastroenterology
- Vol. ume 12, 111-120
Open AccessManagement of microscopic colitis: challenges and solutions
Microscopic colitis (MC) is a chronic inflammatory bowel disease characterized by nonbloody diarrhea in the setting of normal appearing colonic mucosa. MC has two main subtypes based on histopathologic features, collagenous colitis and lymphocytic colitis. Management of both subtypes is the same, with treatment goal of reducing the number of bowel movements and improving consistency. First-line treatment involves counseling the patient about decreasing their risk factors, like discontinuing smoking and avoiding medications with suspected association such as NSAIDs, proton pump inhibitor, ranitidine, and sertraline. Starting loperamide for immediate symptomatic relief is used as an adjunct to therapy with glucocorticoids. Budesonide is considered first-line treatment for MC given its favorable side effect profile and good efficacy, though relapse rates are high. Systemic glucocorticoids should be reserved to patients unable to take budesonide. In glucocorticoid refractory disease, medications that have been tried include cholestyramine, bismuth salicylate, antibiotics, probiotics, aminosalicylates, immunomodulators, and anti-tumor necrosis factor-alpha inhibitors. More research is needed for the creation of a systematic stepwise approach for relapsing and refractory disease.